Precigen Q2 2020 Earnings Report

Precigen's financial performance for Q2 2020 was announced, featuring a total revenue of $30.4 million and a net loss of $43.4 million.

Key Takeaways

Precigen reported a second-quarter revenue of $30.4 million and a net loss of $43.4 million, or $(0.26) per basic share. The company highlighted progress in clinical trials and the development of its UltraPorator manufacturing device.

Advanced the development of UltraPorator™ electroporation device, initiating cGMP manufacturing and technology transfer.

Initiated patient dosing in the third dose level of the Phase 1 clinical trial of PRGN-3005 UltraCAR-T for advanced ovarian cancer.

AG019 ActoBiotics™ Phase 1b monotherapy study met the primary endpoint for safety and tolerability in patients with early-onset type 1 diabetes.

INXN-4001 Phase I trial for heart failure met primary endpoints for safety and feasibility, with preliminary data suggesting improved patient outcomes.

Previous year: -$0.25